Edition:
United Kingdom

Clearside Biomedical Inc (CLSD.OQ)

CLSD.OQ on NASDAQ Stock Exchange Global Market

5.48USD
19 Oct 2018
Change (% chg)

$0.15 (+2.81%)
Prev Close
$5.33
Open
$5.33
Day's High
$5.51
Day's Low
$5.33
Volume
40,858
Avg. Vol
78,495
52-wk High
$15.27
52-wk Low
$5.26

Latest Key Developments (Source: Significant Developments)

Clearside Biomedical Q2 Loss Per Share $0.65
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.65.Q2 EARNINGS PER SHARE VIEW $-0.58 -- THOMSON REUTERS I/B/E/S.CLEARSIDE BIOMEDICAL SAYS REMAIN ON TRACK TO SUBMIT FIRST NDA BEFORE END OF THIS YEAR.CURRENT CASH POSITION SUFFICIENT TO FUND PLANNED OPERATIONS INTO Q4 2019.  Full Article

Clearside Biomedical Announces Positive Topline Results From Phase 2 Clinical Trial Of CLS-TA
Thursday, 31 May 2018 

May 31 (Reuters) - Clearside Biomedical Inc ::CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 CLINICAL TRIAL OF CLS-TA USED WITH EYLEA IN PATIENTS WITH DIABETIC MACULAR EDEMA.CLEARSIDE BIOMEDICAL INC - PRIMARY AND SECONDARY ENDPOINTS MET IN 6-MONTH TRIAL.CLEARSIDE BIOMEDICAL INC - PATIENTS TREATED WITH CLS-TA ACHIEVED COMPARABLE VISION IMPROVEMENT WITH FEWER TREATMENTS.CLEARSIDE BIOMEDICAL INC - SUPRACHOROIDAL CLS-TA USED TOGETHER WITH INTRAVITREAL EYLEA WAS GENERALLY WELL TOLERATED.  Full Article

Clearside Biomedical Q3 loss per share $0.72
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Clearside Biomedical Inc ::Clearside Biomedical, Inc. Announces third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.72.Q3 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.  Full Article

Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Clearside Biomedical Inc :Clearside Biomedical announces completion of patient enrollment in phase 2 clinical trial of CLS-TA used together with Eylea in patients with diabetic macular edema.Clearside Biomedical Inc - ‍patient follow-up in Tybee trial is 6 months​.  Full Article

BRIEF-Clearside Biomedical Q1 Loss Per Share $0.62

* CLEARSIDE BIOMEDICAL ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE